TY - JOUR
T1 - Diagnostic utility of immunofixation and free light chain assay in AL amyloidosis
T2 - a systematic review and meta-analysis
AU - Azzam, Muayad
AU - Hamarsha, Qais
AU - Kawtharany, Hassan
AU - Nazzal, Jamil
AU - Alkhader, Aseel
AU - Khraise, Tala
AU - AlMasri, Mohammad Mahmoud
AU - Abou Zeid, Hadi Khaled
AU - Alwan, Iktimal
AU - Jaber, Nour
AU - Seftel, Matthew D.
AU - Aguirre, Maria Adela
AU - Boedicker, Deborah
AU - Bumma, Naresh
AU - Carroll, Antonia
AU - Comenzo, Raymond
AU - Cook, Joselle
AU - Dasgupta, Noel
AU - De La Torre, Alfredo H.
AU - Dispenzieri, Angela
AU - Jamal, Faizi
AU - Khouri, Jack
AU - Picken, Maria M.
AU - Raza, Shahzad
AU - Leung, Nelson
AU - Sanchorawala, Vaishali
AU - Sarswat, Nitasha
AU - Shaikh, Hira
AU - Singh, Daulath
AU - Kukreti, Vishal
AU - Mustafa, Reem A.
N1 - Publisher Copyright:
© 2026 American Society of Hematology
PY - 2026/8/11
Y1 - 2026/8/11
N2 - In this systematic review, we aimed to assess the sensitivity of serum immunofixation (SIFE), urine immunofixation (UIFE), and serum free light chain (sFLC) in detecting plasma cell dyscrasia associated with light chain (AL) amyloidosis. We searched the literature using PubMed, Embase, and CENTRAL databases since inception through March 2024. We included studies reporting the diagnostic accuracy of immunofixation and/or sFLC in patients with AL amyloidosis. We used the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach to assess the certainty of the evidence and QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies-2) to assess the risk of bias. After deduplication, 29 237 records were screened, and 44 studies (n = 18 071) were included. For the meta-analysis, 28 studies reported sensitivity for SIFE (n = 3390), 24 studies for UIFE (n = 2830), 19 studies for SIFE and UIFE (n = 2819), 21 studies for sFLC ratio (n = 3678), 6 studies for SIFE and sFLC ratio (n = 372), 3 studies for UIFE and sFLC ratio (n = 242), and 10 studies for all 3 tests (n = 1430). Pooled sensitivities were as follows: SIFE, 0.68 (95% confidence interval [CI], 0.62-0.73); UIFE, 0.77 (95% CI, 0.72-0.81); SIFE and UIFE, 0.89 (95% CI, 0.84-0.93); and sFLC ratio, 0.82 (95% CI, 0.78-0.86). When SIFE, UIFE, and sFLC ratio were combined, the sensitivity reached 0.99 (95% CI, 0.96-1.00). The high sensitivity of combining SIFE, UIFE, and sFLC ratio supports their use as a reliable initial testing strategy to raise suspicion for AL amyloidosis and guide decisions regarding future diagnostic modalities.
AB - In this systematic review, we aimed to assess the sensitivity of serum immunofixation (SIFE), urine immunofixation (UIFE), and serum free light chain (sFLC) in detecting plasma cell dyscrasia associated with light chain (AL) amyloidosis. We searched the literature using PubMed, Embase, and CENTRAL databases since inception through March 2024. We included studies reporting the diagnostic accuracy of immunofixation and/or sFLC in patients with AL amyloidosis. We used the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach to assess the certainty of the evidence and QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies-2) to assess the risk of bias. After deduplication, 29 237 records were screened, and 44 studies (n = 18 071) were included. For the meta-analysis, 28 studies reported sensitivity for SIFE (n = 3390), 24 studies for UIFE (n = 2830), 19 studies for SIFE and UIFE (n = 2819), 21 studies for sFLC ratio (n = 3678), 6 studies for SIFE and sFLC ratio (n = 372), 3 studies for UIFE and sFLC ratio (n = 242), and 10 studies for all 3 tests (n = 1430). Pooled sensitivities were as follows: SIFE, 0.68 (95% confidence interval [CI], 0.62-0.73); UIFE, 0.77 (95% CI, 0.72-0.81); SIFE and UIFE, 0.89 (95% CI, 0.84-0.93); and sFLC ratio, 0.82 (95% CI, 0.78-0.86). When SIFE, UIFE, and sFLC ratio were combined, the sensitivity reached 0.99 (95% CI, 0.96-1.00). The high sensitivity of combining SIFE, UIFE, and sFLC ratio supports their use as a reliable initial testing strategy to raise suspicion for AL amyloidosis and guide decisions regarding future diagnostic modalities.
UR - https://www.scopus.com/pages/publications/105046147970
UR - https://www.scopus.com/pages/publications/105046147970#tab=citedBy
U2 - 10.1182/bloodadvances.2025019530
DO - 10.1182/bloodadvances.2025019530
M3 - Review article
C2 - 41979328
AN - SCOPUS:105046147970
SN - 2473-9529
VL - 10
SP - 5293
EP - 5307
JO - Blood Advances
JF - Blood Advances
IS - 15
ER -